NNovo Nordisk Read More Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow2026-04-30 Novo Nordisk’s stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift…